Because each patient responds differently to treatment, it is important that patients complete the full TEPEZZA treatment course of 8 IV infusions as studied in clinical trials4
Patient treated with TEPEZZA in a clinical trial. Patient completed a full course (8 IV infusions) of treatment with TEPEZZA.
Results shown are with no surgical intervention. Individual results may vary.4,5
For patients who had a proptosis response at Week 24 and then experienced a flare,* the majority (63%; 5 of 8) achieved improvements in proptosis (≥2-mm reduction from OPTIC-X baseline) with a second course of TEPEZZA at Week 24 in OPTIC-X7†
The OPTIC-X patients who did not experience a ≥2-mm improvement in proptosis (n=3) had reductions relative to their OPTIC baseline (3 mm, 3 mm, and 4 mm, respectively)7
Patients losing ≥2 mm of their Week 24 proptosis improvement during the 48-week OPTIC follow-up period, even if
their proptosis was still substantially better than at OPTIC baseline7
-OR-
Patients experiencing an increase in CAS
of at least 2 points from OPTIC Week 24, with an absolute CAS of at least 4 in the study eye7
-AND-
Presence of
symptoms7
OPTIC-X evaluated safety and efficacy of TEPEZZA in patients who were proptosis nonresponders at OPTIC Week 24 or proptosis responders at Week 24 but flared during 48-Week follow-up period.